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It has traditionally been thought that disease burden is the primary deter-
minant of local control after breast cancer surgery. Th e selection criteria for 
breast-conserving therapy (BCT) are related to the extent of disease in the breast 
as measured by margin status, multicentricity, and extent of calcifi cations as 
well as the ability to safely deliver radiotherapy. Biologic factors, such as tumor 
histology, grade, estrogen receptor (ER), progesterone receptor (PR), and HER2 
status, are not considered as selection factors when deciding between BCT and 
mastectomy. Th e recognition that breast cancer is actually a group of genetically 
distinct diseases with diff ering prognosis has dramatically changed the approach 
to systemic therapy, with ER, PR, and HER2 status the primary determinants of 
treatment regardless of disease burden (i.e., node positive versus node negative). 
While this paradigm shift is well accepted, less attention has been paid to the 
impact of molecular subtype on local therapy outcomes.
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Molecular Subtype and Presenting Features of Cancer
In a retrospective study of 6 072 patients undergoing surgery at Memorial 
Sloan-Kettering Cancer Center during the era when ER, PR, and HER2 were 
routinely obtained, signifi cant variation in presenting tumor features was observed 
on the basis of these markers. As expected, patients with ER positive cancers 
were older and signifi cantly less likely to have grade III tumors. Patients whose 
cancers overexpressed HER2 were signifi cantly more likely to have multifocal or 
multicentric cancers (p < 0.001) and cancers with an extensive intraductal compo-
nent (p < 0.0001). In multivariate analysis, after adjustment for age, tumor size, 
and grade, ER negative, HER2 positive cancers were 1.6 time (95% confi dence 
interval [CI], 1.2-2.1; p < 0.0001) more likely than ER/PR positive, HER2 nega-
tive cancers to be multifocal or multicentric. Th e presence and extent of nodal 
involvement also vary with subtype. In spite of their poor prognosis, ER, PR, 
and HER2 negative (“triple negative”) cancers were less likely than ER positive, 
HER2 negative cancers to have nodal involvement after adjusting for age, grade, 
and size (odds ratio [OR], 0.6; 95% CI, 0.5-1.7; p < 0.0001). In contrast, HER2 
positive, ER negative cancers were signifi cantly more likely to have involvement 
of 4 or more nodes (OR, 1.8; 95% CI, 1.3-2.4; p < 0.0001) [1]. Others have also 
reported a lower incidence of nodal involvement in triple negative cancers [2, 3].
Impact of Molecular Subtype on Local Therapy Outcomes
It is already clear that intrinsic tumor biology and the availability of targeted 
therapy have a major impact upon the outcomes of local therapy. Single-institution 
studies [4] demonstrated that patients with estrogen receptor positive, HER2 
negative cancers have lower rates of local recurrence (LR) after BCT than do 
patients with ER negative, PR negative, and HER2 negative cancers. In a metaa-
nalysis of 7 174 patients undergoing BCT, the relative risk of LR was 0.49 for 
non-triple-negative cancers compared with triple-negative cancers (95% CI, 
0.33-0.73; p = 0.0005) [5].
Th is increased rate of LR in triple-negative cancers is not improved with the use 
of more extensive surgery. In a study of 535 patients with triple-negative cancers, 
Pilewskie et al. [6] found no signifi cant diff erence in LR with the use of margins 
greater than 2 mm (n = 464) versus margins  2 mm (n = 71) after adjusting 
for systemic therapy use (5.1% versus 7.3%; p = 0.08). Th is fi nding is confi rmed 
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by 3 retrospective studies that show no diff erence in rates of LR among T1 and 
T2, N0 patients, with triple-negative cancer undergoing BCT or mastectomy 
without radiation therapy (RT) [7].
A metaanalysis examining LR after mastectomy by subtype in 5 418 patients 
demonstrated a decreased risk of LR after mastectomy in non-triple-negative 
versus triple-negative cancers (relative risk [RR], 0.66; 95% CI, 0.53-0.83; 
p = 0.0003) [5]. Th us, unlike the situation with disease burden, where heavier 
disease burden is an indication for more extensive surgery (mastectomy rather 
than BCT), more extensive surgery does not overcome bad biology.
It is, however, increasingly apparent that eff ective targeted therapy improves 
local therapy outcomes, as illustrated in patients with HER2 overexpressing 
cancers. In studies antedating the use of adjuvant trastuzumab, patients with 
HER2 overexpressing cancers had rates of LR similar to those seen in triple-nega-
tive cancers [4]. Th e use of adjuvant trastuzumab reduces LR by approximately 
40% compared with chemotherapy alone in randomized trials [8]. In studies at 
Memorial Sloan-Kettering Cancer Center, adjuvant trastuzumab reduced the 
3-year rate of LR after BCT from 7% to 1% (p = 0.01) [9], and also decreased 
the rate of LR after mastectomy (1.5% versus 6.6%; p = 0.04). Th ese fi ndings, 
while helping to more accurately defi ne the risk of LR in an individual, do not 
help to select one treatment over another. Eff orts to identify genetic signatures 
that signal patients at higher risk of LR after BCT than after mastectomy have 
been unsuccessful to date; however, evidence is emerging that within molecular 
subtypes, genetic profi ling may identify groups at higher and lower risk of LR, 
potentially allowing tailoring of local therapy. Mamounas et al. [10] showed that 
in node-negative breast cancer patients receiving tamoxifen and chemotherapy, 
patients with a low 21-gene recurrence score (Oncotype DX™) had a 10-year 
risk of LR of 1.6% compared with a risk of 7.8% in patients with a high score 
(p = 0.028). Th e same pattern was seen in node-positive patients, where those 
with a low recurrence score had a 10-year LR of 3.3% versus 12.3% in those with 
a high score (p < 0.001 in multivariate analysis) [11]. Th is fi nding was observed 
after both mastectomy and BCT, and in patients with 1-3 involved nodes as well 
as those with 4 or more involved nodes. Th ese fi ndings, if confi rmed, suggest 
that postmastectomy irradiation (PMRT) could be avoided in patients with 1-3 
involved nodes and low 21-gene recurrence scores, and even in patients with 
involvement of 4 or more nodes and low scores, a group for whom PMRT has 
long been standard.
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Implications for Axillary Management
Th e benefi cial eff ect of systemic therapy on local control in the breast raises the 
possibility that the extent of axillary surgery, with its associated morbidity, could 
be reduced in patients receiving systemic therapy. Th is was the question addressed 
in the American College of Surgeons Oncology Group (ACOSOG) Z0011 trial. 
In this study, women with clinical T1 and T2, clinically node-negative cancers 
undergoing BCT with whole breast RT who were found to have metastases in 
fewer than 3 sentinel nodes were randomized to completion axillary lymph node 
dissection or no further axillary surgery. After a median follow-up of 6.3 years, 
no diff erence in total locoregional recurrence rate, disease-free survival, or overall 
survival was seen between groups [12]. Th ese results are potentially practice 
changing, but concerns have been expressed that they do not apply to the entire 
spectrum of women undergoing BCT because the population of women entered 
into ACOSOG Z0011 was a particularly low-risk subgroup. In particular, there 
are concerns that younger women and women with ER negative cancers were 
underrepresented in the trial, and that these women might be more likely to have 
a heavy axillary tumor burden.
In August 2010, the Breast Service at Memorial Sloan-Kettering Cancer Center 
adopted as standard clinical practice the elimination of axillary dissection for 
women with fewer than 3 involved sentinel lymph nodes who otherwise met 
ACOSOG Z0011 eligibility criteria. Patients had to be clinically node nega-
tive on physical examination, but were not screened with axillary imaging. Th e 
Memorial Sloan-Kettering Cancer Center nomogram for predicting the like-
lihood of additional nodal metastases in breast cancer patients with a positive 
sentinel node biopsy was not used to estimate the likelihood of residual node 
disease. Axillary dissection was performed for metastases in 3 or more sentinel 
nodes, gross extracapsular extension or matted nodal disease, or if the patient 
required conversion to mastectomy. Between August 2010 and November 2012, 
287 consecutive, unselected patients meeting eligibility criteria were treated: 215 
with macrometastases and 72 with micrometastases detected by hematoxylin 
and eosin staining. Of these, 242 (84%) did not require axillary dissection [13]. 
Dissection was indicated in 29 of 45 patients for 3 or more nodal metastases, 
and for matted nodes or extracapsular extension in the remainder. A comparison 
of patients requiring axillary dissection and those who did not, demonstrated 
no diff erence in median age (60 versus 58 years, p = 0.35), hormone receptor 
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status (13% ER negative versus 10%), or histologic grade between the groups. 
Pathologic tumor size was a median of 0.6 cm larger in the axillary dissection 
group (p < 0.001). Although the median follow-up of 13 months is too short 
to draw any conclusions about the rate of regional control, there have been no 
nodal recurrences in either group. One patient is the sentinel node biopsy-only 
group has had as in-breast recurrence, and 3 patients in the axillary dissection 
group have developed distant metastases. A comparison of the patients avoiding 
axillary dissection in this consecutive, unselected series to those randomized in 
ACOSOG Z0011 [12] demonstrates that the median ages are similar (58 versus 
55 years), tumor sizes did not diff er, and the proportion of ER positive cases 
was actually higher in our series (91% versus 83%). Twenty-seven percent of 
patients in the axillary dissection arm of ACOSOG Z0011 had additional nodal 
metastases, while the Memorial Sloan-Kettering Cancer Center nomogram [14] 
predicted additional metastases in 34% of patients having sentinel node biopsy-
only in our study. In contrast, 70% of patients undergoing axillary dissection in 
our study had additional nodal disease, indicating that the selection criteria used 
for axillary dissection (3 or more positive sentinel nodes, matted nodes, gross 
extracapsular extension) reliably identifi ed a group at high risk of residual nodal 
disease. Our fi ndings suggest that the patients entered into ACOSOG Z0011 
are more representative of the general population of clinically node-negative 
women undergoing BCT than was initially thought, and that the morbidity 
of axillary dissection can be avoided in the majority of clinically node-negative 
patients undergoing BCT. Although further follow-up is needed, this approach 
illustrates the principle that as the eff ectiveness of other therapies increases, the 
extent of surgery may be decreased and excellent local control is still maintained.
Th ese results also illustrate the ability to change standard surgical paradigms based 
on the use of the multimodal therapy. In the National Surgical Adjuvant Breast 
and Bowel Project (NSABP) B04 trial, in the simple mastectomy alone arm, 
where no systemic therapy or RT was used, the ratio of nodal disease left behind 
to axillary fi rst failure was 2.2 to 1 [15]. In ACOSOG Z0011, this increased to 
30 to 1 in the setting of virtually all patients receiving systemic therapy and whole 
breast RT [12]. Th is opens the door to the possibility that less surgery in the breast 
– for example, removal of only the gross tumor – without obsessive concern for 
margins, could result in high rates of local control in selected subgroups. Yet, at 
the same time that recognition of the impact of other therapies on local outcomes 
has allowed us to decrease surgery in the axilla, improvements in imaging may 
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be contributing to more extensive surgeries in the breast. Magnetic resonance 
imaging (MRI) detects cancer not identifi able by other means in approximately 
16% of patients [16]. In a metaanalysis examining the impact of preoperative 
MRI on type of surgery, after adjusting for age, use of MRI increased the odds of 
mastectomy 3-fold, without reducing rates of re-excision for positive margins [17].
As molecular imaging continues to improve, it is very likely that an increasing 
number of patients will have disease too extensive for BCT – at least according 
the standards developed in the 1980s, and which continue to be used today. In 
the short term, the real challenge for local therapy is to re-defi ne our concept 
of what extent of surgical reduction of tumor burden is needed to provide high 
levels of local control, recognizing that this is likely to diff er among, and even 
within, molecular tumor subtypes. Looking ahead, the one thing that is clear is 
that the “one size fi ts all” approach to local therapy that has served us well for 
the past 30 years is not the path to future success.
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